Navigation Links
InVitria Touts Product Advantages at Cambridge's Cell Culture Conference
Date:9/24/2008

FORT COLLINS, Colo., Sept. 24 /PRNewswire/ -- InVitria (http://www.InVitria.com) addressed attendees at Cambridge Healthtech Institute's 4th Annual "Optimizing Cell Culture Development" Conference on September 15-16 in Boston, Massachusetts and announced its most recent results optimizing cell culture media using its product line of animal free cell culture ingredients. (http://www.healthtech.com/ocb/overview.aspx?c=562)

In a presentation of scientific studies with InVitria's Cellastim and Lacromin, Steve Pettit, Director of InVitria's Cell Culture Group, noted, "The growth and productivity results in CHO cell lines are quite impressive and not achievable with other sources of albumin or transferrin supplements. Cellastim has shown growth and productivity up to 50% better than the next best alternative. Similar impressive results with the use of Lacromin have previously been published by our team(1)," said Pettit.

"We continue to show powerful results of Cellastim and Lacromin in cell culture media for a variety of cell lines including CHO, Hybridoma, Vero and NS0 cells. Since these are well defined supplements, they help our customers achieve both their regulatory and manufacturing goals. These are the only supplements available that not only improve cell culture performance, but do this while maintaining a defined and animal free media," said Scott Deeter, InVitria's President.

About InVitria (http://www.InVitria.com)

InVitria has developed animal free cell culture ingredients that enhance productivity, safety and time to market for companies in the biopharmaceutical, cell culture, life science research and diagnostics industry. InVitria's animal free product line includes:

-- Cellastim - Cellastim is a recombinant albumin that is used as a cell culture ingredient and biopharmaceutical formulation excipient. Cellastim has been shown to improve mammalian cell culture productivity. Cellastim also has been an effective component in stem cell media and primary cell media.(see http://www.Cellastim.com)

-- Lacromin - Lacromin is recombinant human lactoferrin, a growth factor that also delivers iron similar to transferrin in cell culture media. (see http://www.Lacromin.com)

-- Lysobac - Lysobac is a bacterial cell lysis agent that is more efficient and more consistent compared to chicken lysozyme and provides higher recombinant protein yield compared with mechanical cell lysis. Lysobac is used in bacterial fermentation to improve recombinant protein yields.(see http://www.Lysobac.com)

(1) Huang et al. Bioactive Recombinant Human Lactoferrin Stimulates Mammalian Cell Growth. Society for InVitro Biology. InVitro Cell Develop. Biology. May 6, 2008.

For more information about the InVitria line of products, please e-mail info@InVitria.com or call 1-800-916-8311.


'/>"/>
SOURCE InVitria
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InVitria Sponsors Cambridge Healthtechs Optimizing Cell Culture Development Conference
2. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
3. InVitria Expands Sales Team
4. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
5. Gores Legacy of Innovation Extends From Products to Processes
6. Martek is Now the Sole-Source Supplier of ARA for all Infant Formula Products Manufactured by Hochdorf Nutricare
7. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
8. Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment
9. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
10. 2008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expos 14-Year History
11. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... , ... Bactana Animal Health, a company developing natural products aimed at reducing ... the gut microbiota, today announced the closing of its first round of funding. ... Capital Management, LLC and a number of private investors. The company will use the ...
(Date:3/29/2017)... NEWARK, Del. , March 29, 2017 ... medicine company, and W. L. Gore & ... announced a collaborative research agreement whereby the two companies ... delivery device technologies that provide protection from immune rejection. ... has been developing innovative stem cell-derived cell replacement therapies ...
(Date:3/29/2017)... TORONTO , March 29, 2017 /PRNewswire/ -  GeneNews Limited ... of BreastSentry™ , a new risk stratification test for ... reference lab, Innovative Diagnostics Laboratory ("IDL"). BreastSentry incorporates a blood-based ... five-year and lifetime risk for developing breast cancer.   ... BreastSentry measures ...
(Date:3/29/2017)... The Global Microfluidic Chips Market by Manufacturers, Countries, Type ... study on the existing state of the global Microfluidic Chips industry ... and Asia-Pacific , South ... Africa . ... Browse 172 Tables and Figures, 13 Major Company Profiles, spread ...
Breaking Biology Technology:
(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
(Date:3/2/2017)... Summary This report provides all the information ... partnering interests and activities since 2010. Download the ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
Breaking Biology News(10 mins):